{"id":127745,"date":"2026-09-08T17:12:13","date_gmt":"2026-09-08T17:12:13","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/127745\/"},"modified":"2026-09-08T17:12:13","modified_gmt":"2026-09-08T17:12:13","slug":"novartiss-pipeline-just-lost-two-big-bets","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/127745\/","title":{"rendered":"Novartis\u2019s Pipeline Just Lost Two Big Bets"},"content":{"rendered":"<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/67c37bf51b277b436c4efece4df19f547e4e5dbea566d5adb050a4dbfa2f8ab3\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fmoby_896%2Ff2b6a31e02c3cbec858652a22eef6a15.jpg\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Novartis's Pipeline Just Lost Two Big Bets\" height=\"1152\" width=\"928\" class=\"yf-1f8hkhu loader\"\/><\/a> Novartis&#8217;s Pipeline Just Lost Two Big Bets &#8211; Moby           THE GIST          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we&#8217;ll show you why it&#8217;s our #1 pick. <a href=\"https:\/\/moby.co\/get-started?utm_source=yahoo_finance&amp;utm_medium=rss&amp;utm_campaign=bounty&amp;utm_content=top_article_nvidia\" data-ylk=\"slk:Tap%20here.;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Tap here.&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Tap here.<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Drug development can turn billions into zero surprisingly quickly. Novartis just got that reminder twice, with two major Phase III failures sending its shares toward one of their ugliest sessions in decades.  <\/p>\n<p>            WHAT HAPPENED          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis shares dropped around 9% after the Swiss pharmaceutical giant reported disappointing Phase III results for del-desiran, an experimental treatment for myotonic dystrophy type 1.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The HARBOR study failed to demonstrate a statistically significant improvement over placebo on its primary endpoint, video hand opening time, a measure of the muscle stiffness suffered by patients with the rare progressive disorder. That would have hurt on its own.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">It hurt much more because del-desiran came from Novartis&#8217;s $12 billion acquisition of Avidity Biosciences, completed in February. The deal brought three late-stage neuromuscular programs and an antibody oligonucleotide conjugate platform that management hoped could produce multiple new medicines before 2030.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Del-desiran was the most advanced test of that investment.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">There were some positives buried in the data. The treatment showed signs of clinical activity across secondary endpoints and exploratory analyses, while its safety profile was broadly consistent with previous findings. Novartis will now analyze the complete dataset and discuss potential next steps with regulators.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">But investors did not hang around for the footnotes.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Shares sank roughly 9%, wiping billions from Novartis&#8217;s market capitalization and putting the stock on course for one of its worst trading days on record. And the timing was brutal.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The previous trading day, Novartis shares had already fallen more than 3% after another major drug candidate, pelacarsen, failed its Phase III Lp(a)HORIZON study.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Pelacarsen successfully lowered levels of lipoprotein(a), an inherited cardiovascular risk factor affecting roughly one in five people. Unfortunately, lowering the biomarker did not translate into the result that matters most: significantly fewer cardiovascular deaths, heart attacks, strokes and urgent coronary procedures compared with placebo.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The drug had been viewed as a potential blockbuster, with peak annual sales expectations reaching several billion dollars.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Two pivotal failures in rapid succession suddenly turned a pipeline packed with promise into a much harder valuation puzzle.  <\/p>\n<p>             WHY IT MATTERS           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Big pharma companies are basically running relay races against patent cliffs.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. <a href=\"https:\/\/moby.co\/get-started?utm_source=yahoo_finance&amp;utm_medium=rss&amp;utm_campaign=bounty&amp;utm_content=middle_article_30m\" data-ylk=\"slk:Tap%20here.;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Tap here.&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Tap here.<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Today&#8217;s blockbuster eventually loses exclusivity. Cheap competition arrives. Revenue falls. So companies like Novartis constantly need the next generation of medicines ready to pick up the baton. That&#8217;s why these failures matter far beyond two experimental drugs.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis is targeting 5% to 6% annual sales growth between 2025 and 2030, a goal it reiterated despite the latest setback. To hit that target and keep growing afterward, it needs its pipeline to produce multiple large products.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Pelacarsen and del-desiran were supposed to help.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The del-desiran failure is particularly uncomfortable because Novartis paid $12 billion for Avidity only months ago. The acquisition was pitched as a way to strengthen the late-stage pipeline and open multi-billion-dollar opportunities in genetic neuromuscular diseases.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Paying billions for science that later fails is not unusual in pharma. Clinical development is brutal precisely because even promising drugs can collapse at Phase III. But timing changes perception.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">When a flagship asset fails shortly after a major acquisition, investors stop asking only whether the drug works. They start asking whether management paid too much, whether the due diligence was good enough and whether the remaining acquired assets deserve the same confidence.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Pelacarsen creates a different headache. Its failure raises questions about whether reducing Lp(a) itself will reliably reduce cardiovascular events, potentially affecting an entire field being pursued by rivals including Amgen and Eli Lilly.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">So Novartis managed to lose one company-specific bet and shake confidence in a broader therapeutic idea almost simultaneously. That&#8217;s some efficient bad news.  <\/p>\n<p>       WHAT&#8217;S NEXT         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis still has plenty of shots on goal.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The other Avidity programs continue moving forward, while remibrutinib recently delivered positive Phase III results in relapsing multiple sclerosis. The company has also kept its 5% to 6% sales-growth target through 2030. But investors will now apply a much bigger discount to promises about the pipeline.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The immediate questions are whether del-desiran has any viable regulatory path left, what the full pelacarsen data reveal and whether the remaining Avidity assets can justify the $12 billion price tag. The bigger question lands on CEO Vas Narasimhan.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis has used acquisitions and pipeline investment to build the growth engines meant to carry it beyond today&#8217;s blockbusters. Two Phase III failures do not destroy that strategy.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">They do make the next wins considerably less optional.  <\/p>\n","protected":false},"excerpt":{"rendered":"Novartis&#8217;s Pipeline Just Lost Two Big Bets &#8211; Moby THE GIST Our analysts just identified a stock with&hellip;\n","protected":false},"author":2,"featured_media":127746,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[13808,7849,62199,206,6007,57008,155,62296,62295,8465],"class_list":["post-127745","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-avidity","tag-avidity-biosciences","tag-del-desiran","tag-novartis","tag-nvidia","tag-pelacarsen","tag-phase-iii","tag-phase-iii-lpahorizon","tag-the-previous-trading-day","tag-two"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117236540509794559","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=127745"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127745\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/127746"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=127745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=127745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=127745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}